Annual Meeting of the American Society of Clinical Oncology at McCormick Place in Chicago, Ill.
Annual Meeting of the American Society of Clinical Oncology at McCormick Place in Chicago, Ill.

During his first inaugural address in 1933, President Franklin D. Roosevelt famously said, ?the only thing we have to fear is fear itself.?

It was in the midst of the economic Depression and the newly elected president was trying to raise the hopes of a nation in despair suffering also from the throes of psychological depression.

Earlier this month while attending a fundraising dinner for the American Society of Clinical Oncology?s Conquer Cancer Foundation during the society?s 53rd annual meeting in Chicago, I heard another phrase that really resonated with me: ?a world free from the fear of cancer.?

Those words expressed Conquer Cancer?s vision, which I?ve long thought to be a far more realistic goal than those claiming cures, eradication, or ending death and suffering from the more than 200 diseases called cancer.

This was my 29th consecutive annual meeting of the American Society of Clinical Oncology (ASCO), and as a journalist and communicator covering issues, controversies, and trends in oncology for several decades, I?ve witnessed and written about advances in cancer research, treatment, and prevention and control.

Advertisement #3

I?ve concurrently seen ?quality of life? rise to a reasonable and achievable goal for many of the now more than 15 million cancer survivors in the United States alone.

Interestingly, just days before the meeting, Nancy G. Brinker and I co-authored an op-ed in The Hill related to Olivia Newton-John?s recent revelation that she had been diagnosed with metastatic breast cancer 25 years after her initial breast cancer diagnosis.[1]

Brinker, who founded Susan G. Komen, the world?s largest breast cancer charity 35 years ago, and is a breast cancer survivor herself, noted that many breast cancer survivors often live in constant fear that their disease might return and spread after it had been treated.

And that fear factor is still a critical component of how cancer has been perceived in our personal and collective psyches.

Over the years, the stigma of cancer has decreased and today the word once shunned from society is now ubiquitously uttered and heard.

Photo 1.0: Meeting – Siddhartha Mukherjee, MD, DPhil, speaks during Opening Session at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO) on Saturday June 3, 2017.

Its status as the ?Emperor of All Maladies,? as characterized in the Pulitzer Prize-winning book by oncologist Siddhartha Mukherjee, MD, DPhil, and the subsequent PBS documentary by Ken Burns has perhaps outlived its longtime reputation as a death sentence to one commuted in many cases as a manageable and chronic condition.

ASCO and other cancer research meetings have been the venues for announcing many significant scientific advances in understanding, treating, and preventing cancer.

But what was significant this year was ASCO?s inclusion of several psychosocial intervention studies (detailed elsewhere in Onco?Zine) under the meeting?s patient and survivor care track. [2]

One particular study looked at the long-term results of a phase II randomized controlled trial of a psychological intervention–Conquer Fear–to reduce clinical levels of fear of cancer recurrence in breast, colorectal, and melanoma cancer survivors.

The study found that Conquer Fear helped reduce fear of cancer recurrence more than relaxation training, and the point of this article is not to describe the mechanisms of the intervention itself, but to note that these so-called soft science studies are being untaken with their results subsequently disseminated through traditionally harder science conferences.

Several years ago the American College of Surgeon?s Commission on Cancer mandated that its more than 1500 cancer center and hospital members institute a number of psychosocial services for accreditation starting in 2015.

These included patient navigation, psychosocial distress management, and survivorship plans, and were in alignment with previous recommendations from the National Academy of Sciences Institute of Medicine?s reports including From Cancer Patient to Cancer Survivor: Lost in Transition. [3][4]

All of these efforts have yielded a world where many more people are living with cancer rather than dying from it, and a few quantum and many incremental scientific advances have made a tremendous difference in decreasing mortality from the once nearly always-fatal malady.

However, it still remains for cancer to be put into a proper psychological perspective where the conquest of unreasonable fear is far more reasonable than the continued hope of curing something that will always be replaced by other things that make us all mortal.

Which makes Conquer Cancer?s goal to help us deal with coping with the doable both laudatory and achievable.

This is the first in a series of the revival of Eric Rosenthal Reports, formerly featured in Oncology Times.

Last editorial review: June 21, 2017

Featured Image: ASCO 2017? Courtesy: ? 2017 ASCO/Scott Morgan. Used with permission. Photo 1.0: Siddhartha Mukherjee, MD, DPhil. Courtesy: ? 2017 ASCO/Scott Morgan. Used with permission.

Copyright ? 2017 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco?Zine, Oncozine and The Onco?Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.

Advertisement #5
Previous articleStudy Estimates Age-Specific Overall Risk of Breast, Ovarian Cancer among Women with BRCA1/2 Genetic Mutations
Next articleAnti-Leukemic Activity and Safety Data for Gilteritinib in Relapsed
Eric T. Rosenthal is an independent medical journalist specializing in providing insight, perspective, and transparency into various issues, trends, and controversies in oncology, and other areas concerning the politics of health care. He is currently editor-at-large with ADC Review | Journal of Antibody-drug Conjugates and Onco?Zine, special correspondent for MedPage Today, and a contributor to The Hill. Rosenthal was formerly special correspondent for Oncology Times, and senior correspondent and news director for Vital Option International?s nationally syndicated The Group Room cancer talk-radio show. Rosenthal?s reporting is known for its balance providing perspective and context, and taking readers behind the scenes by exploring the ?how? and ?why.?? This is evidenced in his series ?Eric Rosenthal Reports,? which, in June 2017, returned to Onco?Zine. He also co-authors Op-Eds and develops forums for health care-related issues with Nancy G. Brinker, founder of Susan G. Komen, former U.S. State Department Chief of Protocol, Ambassador to Hungary and former U.N. World Health Organization?s Goodwill Ambassador for Cancer Control. Rosenthal?s work has also appeared in the Journal of the National Cancer Institute, Courage magazine, and elsewhere, and he wrote a series of guest posts for PBS/WETA-TV?s ?Producers? Blog? in 2015. He founded EvocaTalk? Research & Reports in 2002 as a service that identifies, explores, and helps resolve issues, and enhances insights through interactive interviews and analysis in both individual and group settings. After beginning his journalism career at the Trenton Times in 1972, where he received a state journalism award for a magazine cover story on schizophrenia research, Rosenthal served in a number of academic public affairs positions before returning to full-time journalism in 1998. These included: editor of publications and public affairs at the Franklin Institute; public relations director at Drexel University; news bureau manager for the American College of Physicians and its Annals of Internal Medicine; and public affairs director at Fox Chase Cancer Center, during which time he founded the National Cancer Institute (NCI)-Designated Cancer Centers Public Affairs Network in 1990. He was named press officer for the American Society of Clinical Oncology?s annual meeting in 1990, and has served on numerous national committees, including the NCI Director?s Consumer Liaison Group, the NCI External Work Group for the Cancer Progress Report, the Oncology Nursing Society?s Consumer Advocacy Panel, and as journalist member of Ken Burns? Cancer: Emperor of All Maladies PBS Documentary Educational Subcommittee. He helped organize two national conferences focusing on the medical-news dissemination process at Cold Spring Harbor Laboratory and the Mayo Clinic; is an global health adviser for Concordia and served as co-chair its Concordia Summit global cancer research collaboration session in 2016 and its cancer burden in Latin America conference in 2017; and practices ?3-D journalism? by organizing and moderating panels and conferences to further develop issues he has covered as a journalist.